Access to a steady supply of obesity drugs remains a challenge even while prices are dropping

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven.

“The medications should be available, the question is at what price and can people sustain that,” said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.

Doctors say the situation forces them to get creative in treating patients, but there is hope that prices may fall more in the future.

THE DRUGS ARE STILL IN HIGH DEMAND

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity.

Zepb